Paul Alan Tempest from Plano, TX, age 55

Resumes

Paul Tempest

view source

Paul Tempest

view source

Paul Tempest

view source

Us Patents

Spirocyclic Compounds
view source
US Patent:

7544695, Jun 9, 2009
Filed:

Nov 16, 2006
Appl. No.:

11/600426
Inventors:

Scott C. Berk - Cambridge MA, US
Joshua Close - Franklin MA, US
Christopher Hamblett - Boston MA, US
Richard W. Heidebrecht - Brookline MA, US
Solomon D. Kattar - Medford MA, US
Laura T. Kliman - Cambridge MA, US
Dawn M. Mampreian - Brookline MA, US
Joey L. Methot - Westwood MA, US
Thomas Miller - Brookline MA, US
David L. Sloman - Boston MA, US
Matthew G. Stanton - Medfield MA, US
Paul Tempest - Brookline MA, US
Anna A. Zabierek - East Kingston NH, US
Assignee:

Merck & Co., Inc. - Rahway NJ
International Classification:

A61K 31/438
C07D 498/10
US Classification:

514278, 546 19
Abstract:

The present invention relates to a novel class of substituted spirocyclic compounds. These compounds can inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the compounds of the instant invention and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of these compounds in vivo.

Melanin Concentrating Hormone Receptor Antagonist
view source
US Patent:

7659276, Feb 9, 2010
Filed:

Feb 6, 2009
Appl. No.:

12/367083
Inventors:

Christopher Hulme - Indianapolis IN, US
Paul Tempest - Brookline MA, US
Vu Ma - Simi Valley CA, US
Thomas Nixey - Newbury Park CA, US
Guity Balow - Fallbrook CA, US
Assignee:

Amgen, Inc. - Thousand Oaks CA
International Classification:

A61K 31/41
A61K 31/4439
A61K 31/454
A61K 31/496
US Classification:

51425309, 51425405, 544364, 544366
Abstract:

Novel compounds, or pharmaceutically-acceptable salts, tautomers or prodrugs thereof, of Formula I.

Inhibitors Of Janus Kinases
view source
US Patent:

7763634, Jul 27, 2010
Filed:

Jun 5, 2007
Appl. No.:

12/227959
Inventors:

Jonathan R. Young - Southborough MA, US
Andrew Haidle - Cambridge MA, US
Paul Tempest - Brookline MA, US
Michelle Machacek - Boston MA, US
Assignee:

Merck & Co., Inc. - Rahway NJ
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:

A61K 31/4745
C07D 471/02
US Classification:

514287, 546 64, 544125, 544242, 544361, 5142328, 514253, 514256
Abstract:

The instant invention provides for tetracyclic compounds that inhibit the four known mammalian JAK kinases (JAK1, JAK2, JAK3 and TYK2) and PDK1. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting the activity of JAK1, JAK2, JAK3 TYK2 and PDK1 by administering the compound to a patient in need of treatment for myeloproliferative disorders or cancer.

Spirocyclic Compounds
view source
US Patent:

7834026, Nov 16, 2010
Filed:

Nov 17, 2006
Appl. No.:

12/085396
Inventors:

Scott C. Berk - Cambridge MA, US
Joshua Close - Franklin MA, US
Christopher Hamblett - Boston MA, US
Richard W. Heidebrecht - Brookline MA, US
Solomon D. Kattar - Medford MA, US
Laura T. Kliman - Cambridge MA, US
Dawn M. Mampreian - Brookline MA, US
Joey L. Methot - Westwood MA, US
Thomas Miller - Brookline MA, US
David L. Sloman - Boston MA, US
Matthew G. Stanton - Medfield MA, US
Paul Tempest - Brookline MA, US
Anna A. Zabierek - East Kingston NH, US
Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:

A01N 43/42
A01N 43/12
A01N 43/26
A61K 31/44
A61K 31/34
A61K 31/335
C07D 237/00
C07D 239/00
C07D 241/00
C07D 491/10
C07D 491/20
C07D 495/10
C07D 495/20
C07D 497/10
C07D 497/20
C07D 311/96
C07D 313/06
C07D 313/20
C07D 315/00
US Classification:

514278, 514462, 544230, 546 19, 549331
Abstract:

The present invention relates to a novel class of substituted spirocyclic compounds, represented by the following structural Formula: I Wherein A, B and D are independently selected from CR, NR, C(O) and O; E is selected from a bond, CR, NR, C(O) and O; wherein at least one of A, B, D or E is CR; and provided that when A is O, then E is not O; G is CR; R is selected from NHand OH; These compounds can inhibit histone deacetylase and are suitable for use in selectively inducing termin differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the compounds of the instant invention and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of these compounds in vivo.

Protein Kinase Modulators And Method Of Use
view source
US Patent:

7880000, Feb 1, 2011
Filed:

May 9, 2005
Appl. No.:

11/126000
Inventors:

Stephanie D. Geuns-Meyer - Medford MA, US
Brian L. Hodous - Cambridge MA, US
Stuart C. Chaffee - Cambridge MA, US
Paul A. Tempest - Brookline MA, US
Philip R. Olivieri - Medford MA, US
Rebecca E. Johnson - Arlington VA, US
Brian K. Albrecht - Cambridge MA, US
Vinod F. Patel - Acton MA, US
Victor J. Cee - Mansfield MA, US
Joseph L. Kim - Wayland MA, US
Steven Bellon - Wellesley MA, US
Xiaotian Zhu - Newton MA, US
Yuan Cheng - Newbury Park CA, US
Ning Xi - Thousand Oaks CA, US
Karina Romero - Cambridge MA, US
Hanh Nho Nguyen - Arlington MA, US
Holly L. Deak - Brookline MA, US
Assignee:

Amgen Inc. - Thousand Oaks CA
International Classification:

C07D 401/14
C07D 403/14
A61K 31/53
A61K 31/4427
A61K 31/506
A61P 19/02
A61P 35/00
US Classification:

544320, 544322, 544182, 514272, 514274, 514242
Abstract:

The present invention relates to chemical compounds having a general formula I.

Phosphorus Derivatives As Histone Deacetylase Inhibitors
view source
US Patent:

7981874, Jul 19, 2011
Filed:

Jul 16, 2007
Appl. No.:

12/309459
Inventors:

Joshua Close - Franklin MA, US
Jonathan Grimm - Newton MA, US
Solomon Kattar - Arlington MA, US
Thomas A. Miller - Brookline MA, US
Karin M. Otte - Newton Center MA, US
Scott Peterson - Somerville MA, US
Phieng Siliphaivanh - Brookline MA, US
Paul J. Tempest - Brookline MA, US
Kevin J. Wilson - West Newton MA, US
David J. Witter - Norfolk MA, US
Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:

A61K 31/662
A61K 31/683
A61K 31/67
A61K 31/675
A61K 31/4747
A61K 31/4545
A61K 31/4436
A61K 31/415
A61K 31/427
C07F 9/28
C07F 9/53
C07F 9/40
C07F 9/32
C07F 9/6571
C07F 9/6584
C07D 333/20
C07D 277/50
C07D 231/40
C07D 221/20
C07F 9/58
C07F 9/59
US Classification:

514110, 514119, 514336, 514370, 514407, 514438, 544 1, 546 16, 546 19, 546 22, 548193, 5483714, 549 6
Abstract:

The present invention relates to a novel class of phosphorus derivatives. The phosphorus compounds can be used to treat cancer. The phosphorus compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the phosphorus derivatives and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of the phosphorus derivatives in vivo.

Histone Deacetylase Inhibitors With Aryl-Pyrazolyl-Motifs
view source
US Patent:

8026260, Sep 27, 2011
Filed:

Oct 30, 2006
Appl. No.:

12/084268
Inventors:

Joshua Close - Franklin MA, US
Solomon Kattar - Arlington MA, US
Thomas A. Miller - Brookline MA, US
David Sloman - Boston MA, US
Matthew G Stanton - Medfield MA, US
Paul Tempest - Brookline MA, US
David J. Witter - Norfolk MA, US
Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:

A61K 31/4439
A61K 31/415
A61K 31/423
A61K 31/425
A61K 31/4245
C07D 401/02
C07D 271/10
C07D 277/20
C07D 231/10
US Classification:

514341, 514364, 514365, 514375, 514406, 5462754, 548143, 548146, 548202, 548235, 5483561, 5483461, 5483731
Abstract:

The present invention relates to a novel class of histone deacetylase inhibitors with aryl-pyrazolyl motifs. The compounds of this invention can be used to treat cancer. The compounds of this invention are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The present invention further provides pharmaceutical compositions comprising the compounds of this invention and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of the compounds of this invention in vivo.

Aryl-Fused Spirocyclic Compounds
view source
US Patent:

8119652, Feb 21, 2012
Filed:

May 14, 2007
Appl. No.:

12/227417
Inventors:

Christopher Hamblett - Boston MA, US
Solomon Kattar - Arlington MA, US
Dawn Mampreian - Boston MA, US
Joey Methot - Westwood MA, US
Thomas Miller - Brookline MA, US
Paul Tempest - Brookline MA, US
Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:

A61K 31/438
C07D 491/10
C07D 491/107
US Classification:

514278, 546 18, 546 20
Abstract:

The present invention relates to a novel class of aryl-fused spirocyclic compounds. These compounds can inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the compounds of the instant invention and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of these compounds in vivo.